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1. Introduction 
The principal sites of calcitonin biosynthesis are 
the C-cells of the thyroid gland in mammals and the 
ultimobranchial body in birds, reptiles and fish. The 
amino acid sequences of the thyrogenic calcitonins 
from four species are known and two, the human 
[l] and the porcine [2] hormones, have been 
synthesized [3,4,5]. Attempts to elucidate the 
sequence of and synthesize ultimobranchial peptides, 
on the other hand, have up to now only succeeded in 
the case of salmon calcitonin [6,7], though others 
have been isolated in highly purified form. The 
calcitonins so far obtained from ultimobranchial 
glands exhibit greater biological activity in rat assays 
than dhose of thyroid origin [8]. This must be 
attributable to some particular amino acids, since the 
sequential differences between the thyroid hormones, 
which are all roughly equal in activity, are as great or 
even greater than the differences between them and 
the ultimobranchial peptides. 
HCT: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
In contrast to that of other peptide hormones, e.g. 
corticotropin, parathyroid hormone or glucagon, the 
biological potency of the calcitonin peptides depends 
to a great extent on the presence of an intact 
C-terminus. As was shown earlier, curtailment of the 
porcine thyrocalcitonin chain [9] by a single amino 
acid, or even by the removal of the amide group at 
C-terminal proline, drastically reduced the hypo- 
calcaemic activity of the peptide. Similar findings 
were made with HCT* (unpublished observations). 
One of the conspicuous differences between HCT and 
SCT 1 is the more hydrophilic character of the 
C-terminal region of the latter (formulae fig. 1). In 
view of the remarkably potent biological activity of 
SCT 1 it was therefore of interest to study the 
influence of particular amino acids close to the 
C-terminus. 
* Abbreviations: HCT: human calcitonin = calcitonin M [ 1 ] ; 
SCT 1: salmon calcitonin as first isolated; SCT 2: iso hormone; 
SCT 3: iso hormone. 
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H-Cys-Gly-Asn-Leu-Ser-Thr-Cys-Met-Leu-Gl~Thr-Tyr-Thr-Gln-Asp-Ph~~n-Lya-Ph~His-ThrcPhe-Pro-GIle-Gl~Val-Gly-Ala-Pro-NH 
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SCTl: 1 2 3 4 5 6 7 6 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 
I I 
~Cys-Ser-Asn-Leu-SeF-Thr-Cys-Val-Leu_G1e~Gln-G1u-Lsu-His-Lys-Leu-G1n-Thr-Tyr-Pro-Arg-Thr-Asn-ThrGly-SerGl~Th~P~~NH 
2 
Fig. 1. Chemical structures of human calcitonin (HCT) and salmon calcitonin (SCT 1). 
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Fig. 2. Abbreviated formulae of calcitonin preparations tested (upper panel) and discussed (lower panel). HCT and its two 
analogues were tested in 6-point assays as shown in fig. 2. The activities of SCT 1 and the two iso hormones SCT 2 and SCT 3 were 
taken from ref. [ 91. All activities were expressed in relation to HCT, which was arbitrarily set at 1. 
In this communication, the significance of the 
amino acids in positions 29 and 31 of the HCT chain 
is examined. In this peptide these positions are 
respectively occupied by valine and alanine. A syn- 
thetic analogue in which these amino acids had been 
replaced by the corresponding amino acids of SCT 1, 
i.e. serine and threonine showed five times greater 
hypocalcaemic activity than natural HCT and a 
slightly longer duration of action. Reversal of their 
sequence to Ala*’ and Va13’, as they occur in two 
isohormones of SCT 1 [ 10,111, yielded a synthetic 
analogue of HCT with very much weaker hypo- 
calcaemic potency. It displayed less than 10% of the 
activity of HCT, and its duraction of effect was also 
shorter. The importance of these two positions is 
discussed by reference to XT 1 and its isohormones 
(formulae fig. 2). 
cribed for the synthesis of HCT [3]. Both prepara- 
tions were obtained in form of the hydrochlorides. 
They were injected in 0.4 ml acetate buffer solution 
(pH 4.6) into female rats of the Sprague-Dawley 
strain (Tierfarm, Sisseln) weighing loo-120 g. The 
animals had been fed a standard laboratory diet and 
kept under controlled lighting conditions. Prior to 
each experiment, they were starved for 16 hr, but 
allowed water. The hypocalcaemic potency of the 
substances was determined by the method of Kumar 
et al. [lo]. Plasma calcium concentrations were 
measured by flame photometry. The areas covered by 
the concentration curves were determined by 
planimetry, one hour being plotted on the abscissa as 
2 cm, and 0.1 mEq Ca” per litre of plasma on the 
ordinate as 1 cm. 
3. Results 
2. Materials and methods 
The two analogues [Ser*‘, Thr3’ ]HCT and [Ala*‘, 
Va131 ]HCT were synthesized by fragment condensa- 
tion procedures, closely following the pathway des- 
3.1. Hypocalcaemic potency (fig. 3) 
The substitution of Ser*’ and Thr3’ for Val*’ and 
Ala31 in the HCT molecule produced an analogue 
([Ser*‘, Thr3’]HCT) with a hypocalcaemic potency 
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Fig. 3. Dose-response regression lines of the hypocalcaemic 
activity measured 50 min after an intravenous injection of 
HCT and the two analogues [Serz9, Va13r]HCT. Each point 
represents the means for 15-20 rats r SEM. 
about five times greater than that of HCT. Reversal 
of the sequence of the amino acids to Ala” and Val” 
yielded an analogue ( [Ala2’, Val”] HCT) which only 
exerted a maximal hypocalcaemic effect at a very 
high dose. Since it showed a flatter regression line 
than HCT, the two peptides are not strictly compar- 
able. It is noteworthy that at threshold doses [Ala2’, 
Va131]HCT only displayed about 5% of the activity 
of HCT’ 
3.2. Duration of hypocalcaemic (fig. 4) 
A subcutaneous dose of 30 pg/kg of HCT provoked 
hypocalcaemia persisting for slightly more than 2 hr. 
The plasma calcium concentration reached its mini- 
mum 1 hr after the administration of the peptide, and 
thereafter increased again rapidly. [Ser2’, Thr3 ‘1 HCT 
(30 pg/kg,s.c.) evoked a hypocalcaemic effect of 
about 2 hr duration. Minimum values were reached 
1 hr after administration and persisted for another 
hour. Total hypocalcaemia was about 25% greater 
than that elicited by the same dose of HCT. [Ala2’, 
Va131]HCT (30 E.cg/kg,s.c.) evoked a hypocalcaemic 
effect of about 2 hr duration. Minimum values were 
reached M hour after administration and persisted for 
a further ~Yz hr. The decrease was similar to that 
produced by HCT, but basal values were regained 
more quickly than after the injection of either HCT 
or [Ser 2p Thr3’ ] HCT. The areas covered by these ,
time-curves were 65 cm2 for HCT, 106 cm2 for 
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Fig. 4. Time-course of hypocalcaemia elicited by a single 
subcutaneous dose of 30 &kg HCT or the two analogues 
[Se?‘, Th?‘]HCTand [Alaz9, Val”‘]HCT. Each point 
represents the mean for 20-30 rats A SEM. 
Per , 2p Thr3’]HCT and 40 cm2 for [Ala2’, Va131]- 
HCT giving a ratio of about 1: 1.6:0.6. 
4. Discussion 
Our results revealed that replacement of Va12’ 
and Ala31 in HCT by Ser2’ and Thr3’, the corre- 
sponding amino acids of the SCT 1 sequence, led to 
a 5-fold increase in potency. On the other hand, when 
Va12’ and Ala” were substituted for Ser2’ and Thr3’ 
in the SCT 1 molecule, its potency was reduced by 
half [ 111. Thus, these two amino acid positions 
appear to be partly responsible for the potent hypo- 
calcaemic activity of SCT 1; the fact that both 
analogues - that of HCT and that of SCT 1 - are less 
active than SCT 1 suggest hat other regions besides 
the C-terminal are also involved. 
Through the work of Keutmann et al. [ 121 the 
structure of two iso hormones of SCT 1 (SCT 2 and 
SCT 2) became known, and they were subsequently 
synthesized [ 131. As is shown in the lower half of 
fig. 2, in their amino acid sequence and composition, 
they are somewhat closer to HCT than SCT 1 is. It is 
interesting to note that the two iso hormones also 
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differ from XT 1 in positions 29 and 3 1 i which are 
occupied respectively by alanine and valine, the same 
amino acids as in HCT but in reverse order. It is 
remarkable that this reversal eads to an HCT-analogue 
displaying only a fraction of the activity of the 
human peptide. In contrast, the calcitonins of salmon 
origin are much less affected if the order of these 
amino acids is changed. The two synthetic analogues 
of SCT 1 with either sequence (valine and alanine, 
or alanine and valine) were reported by Pless et al. 
[ 111 to exhibit equal activity, both being half as 
potent as SCT. Moreover, the iso hormone SCT 2, 
with Ala2’, Val” sequence, has the same degree of 
activity as SCT 1. 
These authors [ 1 I] have also shown that another 
analogue of SCT 1, [Asp”, Phe”]SCT 1 which 
contains the two other amino acids in which the iso 
hormone SCT 2 differs from SCT 1, synthesized to 
unmask a possible compensatory effect of the two 
amino acids, exhibited equal activity as SCT 1, indica- 
ting that these two amino acids per se had no 
influence on hypocalcaemic potency. 
The iso hormone SCT 3 proved to be three times 
less potent than SCT 1 [ 111. Its weaker activity can 
be attributed to the presence of methionine in 
position 8 instead of valine, since our own studies 
revealed an increased activity, when in HCT Met was 
replaced by Val in position 8 (unpublished). 
At present, it is impossible to draw any definitive 
conclusions about the relevance of positions 29 and 
31 as regards the hypocalcaemic potency of CT 
peptides. Although it is certain that the C-terminus is 
an important part of the molecule, it must be con- 
sidered in conjunction with other essential regions. 
Further work is needed to reveal other centres 
affecting biological activity. 
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